←Back to Expert Scholars
Translational Medicine / 转化医学KRAS Combination Therapy
Kathryn Arbour
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Medical Oncologist
32
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Kathryn Arbour has characterized toxicity and efficacy of KRAS G12C inhibitor combinations with immune checkpoint blockade in lung cancer. Her work identified hepatotoxicity risks and informs safer combination sequencing. She leads trials integrating KRAS targeting with other modalities.
Share:
🧪Research Fields 研究领域
lung cancer
KRAS
immunotherapy
hepatotoxicity
combination therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Kathryn Arbour 的研究动态
Follow Kathryn Arbour's research updates
留下邮箱，当我们发布与 Kathryn Arbour（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment